Why Your CJC+Ipamorelin Isn't Working on Retatrutide

Your growth hormone peptides work by triggering a pulse from your pituitary gland, and that pulse only happens cleanly when your insulin is low. Insulin binds to receptors on the somatotroph cells in your pituitary, which are the cells responsible for releasing growth hormone, and when those receptors are occupied, the signal from your peptide gets suppressed before it can do anything useful. This is why every protocol for CJC, Ipamorelin, Tesamorelin, Sermorelin, and any other growth hormone secretagogue carries the same instruction: inject on an empty stomach, at least two hours after your last meal.

That rule was built around normal digestion. When you are on retatrutide, normal digestion no longer applies.

Retatrutide activates three receptors simultaneously, GLP-1, GIP, and glucagon, and its GLP-1 activity does something that directly interferes with the empty-stomach window you are trying to create. It slows gastric emptying, which means the food you ate does not leave your stomach on the schedule your body is used to. It sits longer. It continues being absorbed longer. And because absorption drives insulin release, your insulin stays elevated longer than you would expect.

Researchers measured this directly. In a study using semaglutide, another GLP-1 drug, the time it took for half of a meal to leave the stomach increased from 118 minutes to 171 minutes while on the drug. That is nearly a full hour longer than baseline. At the two-hour mark specifically, there was 25.5 percent more food still sitting in the stomach compared to people not on a GLP-1 drug. At three hours, that number grew to 38 percent more retained. The situation is not improving as you wait, it is worsening relative to what you would expect without the drug.

Retatrutide itself shows the same pattern. Research found that it delayed the absorption peak of a test compound by approximately one hour, with that delay persisting at both Day 30 and Day 79 of use. This is not a temporary adaptation effect that fades as your body adjusts. The mechanism is ongoing as long as the drug is active.

The anesthesiology community took this seriously enough to revisit their fasting guidelines entirely. Patients on GLP-1 drugs were being intubated after what should have been adequate fasting windows and still had solid gastric contents, with documented cases occurring even after seven to eighteen hours of fasting. The clinical response was to treat these patients as if their stomachs might not be empty regardless of how long they had been fasting.

That context matters for understanding what is happening when you inject at the two-hour mark on retatrutide. You have followed the standard rule. You have waited the recommended time. But inside your stomach, the situation looks nothing like what that rule was designed for. Food is still present, absorption is still active, insulin is still circulating, and those insulin molecules are doing exactly what insulin does at your pituitary, which is occupy the receptors that your growth hormone peptide needs clear access to in order to produce a response.

The analogy that makes this click is a gas pedal and a brake pressed at the same time. Your peptide is pressing the gas. Elevated insulin is holding the brake. The result is not a partial growth hormone pulse. The mechanism of action is suppressed at its source, and you are spending money on a compound that cannot do its job in the environment you have created.

The fix is straightforward once you understand the mechanism. Morning injection, before your first meal, after a full night of sleep. Even with retatrutide slowing your digestion, eight to ten hours of overnight fasting gives your stomach time to clear what was there from the previous evening. Insulin has had time to return to baseline. The brake is off. Your peptide can actually work.

One concern people raise here is whether morning timing changes your results compared to evening, which has historically been the more common growth hormone peptide timing because it mirrors the body's natural nocturnal growth hormone peak. The data on this is reassuring. A study comparing morning versus evening growth hormone injections in GH-deficient patients found that 24-hour IGF-1 levels were equivalent between the two timing windows. The pulse matters. The clock it happens on is secondary.

The practical sequencing then becomes: inject your growth hormone peptides first thing in the morning on an empty stomach, wait 30 to 60 minutes for the pulse to complete, then eat your first meal. That post-injection meal matters because your liver needs insulin present to convert the growth hormone your pituitary just released into IGF-1, which is the downstream hormone that actually drives most of growth hormone's effects on body composition. You need the pulse to happen without insulin, and then you need insulin to arrive afterward to process what that pulse produced.

What retatrutide revealed here is a general principle that applies any time you stack compounds with different pharmacological mechanisms. Each drug you add changes the physiological environment that your other drugs are operating in. The rules that were built for single-compound use do not automatically transfer. The two-hour rule for growth hormone peptides was calibrated for a stomach that empties on a normal schedule, and retatrutide fundamentally changed that schedule.

The question is not whether your peptide works. The question is whether the conditions inside your body at the moment you inject it allow it to work.

---

References

1. Urva S, Coskun T, Loghin C, et al. 2023. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity and Metabolism. Finding: Retatrutide at doses ≥3mg delayed acetaminophen Tmax by approximately 1 hour, with effects persisting at Day 30 and Day 79. Source
2. Jensterle M, et al. 2023. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity and Metabolism. Finding: Gastric half-emptying time increased from 118 minutes to 171 minutes on semaglutide. At 2 hours, 25.5% more gastric contents retained vs placebo. At 3 hours, 38% more retained. Source
3. Silveira SQ, et al. 2023. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. Journal of Clinical Endocrinology \& Metabolism. Finding: GLP-1 RA patients had gastric half-emptying of 138 minutes vs 95 minutes on placebo. Patients fasting 7-18 hours still had retained solid gastric contents. Source
4. Jorgensen JO, et al. 1990. Evening versus morning injections of growth hormone in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. Finding: 24-hour IGF-1 levels were equivalent between morning and evening injection timing. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness